Premium
Non‐steroidal anti‐inflammatory drugs and the risk of head and neck cancer: A case‐control analysis
Author(s) -
Becker Claudia,
Wilson Jessica Claire,
Jick Susan S.,
Meier Christoph R.
Publication year - 2015
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.29601
Subject(s) - medicine , aspirin , head and neck cancer , ibuprofen , confounding , case control study , cancer , observational study , population , larynx , medical prescription , surgery , pharmacology , environmental health
Non‐steroidal anti‐inflammatory drugs (NSAIDs) and acetylsalicylic acid (aspirin) have been associated with a reduced risk for certain cancers. We explored the association between use of NSAIDs and the risk of head and neck cancer (HNC). We conducted a case‐control analysis in the UK‐based Clinical Practice Research Datalink (CPRD) among people below the age of 90 years with incident HNC between 1995 and 2013. Six controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the CPRD prior to the HNC diagnosis. Other potential confounders including comorbidities and comedication were also evaluated, and we adjusted our final analyses for BMI, smoking and alcohol consumption. Our analyses included 2,745 HNC cases and 16,470 controls. Aspirin or NSAID use overall did not significantly change the HNC risk. However, patients with six or more prescriptions for ibuprofen were at a statistically significantly reduced risk for HNC (adjusted OR 0.59, 95% CI 0.37–0.94). The HNC risk tended to decrease with increasing cumulative exposure to ibuprofen, and to be more pronounced for cancer of the larynx. To conclude, in this large population‐based observational study we found a decreased risk for HNC associated with regular use of ibuprofen.